308 related articles for article (PubMed ID: 29523784)
21. MYC dysfunction modulates stemness and tumorigenesis in breast cancer.
Liu Y; Zhu C; Tang L; Chen Q; Guan N; Xu K; Guan X
Int J Biol Sci; 2021; 17(1):178-187. PubMed ID: 33390842
[TBL] [Abstract][Full Text] [Related]
22. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
Kessler JD; Kahle KT; Sun T; Meerbrey KL; Schlabach MR; Schmitt EM; Skinner SO; Xu Q; Li MZ; Hartman ZC; Rao M; Yu P; Dominguez-Vidana R; Liang AC; Solimini NL; Bernardi RJ; Yu B; Hsu T; Golding I; Luo J; Osborne CK; Creighton CJ; Hilsenbeck SG; Schiff R; Shaw CA; Elledge SJ; Westbrook TF
Science; 2012 Jan; 335(6066):348-53. PubMed ID: 22157079
[TBL] [Abstract][Full Text] [Related]
23. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
[TBL] [Abstract][Full Text] [Related]
24. MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.
Sullivan DK; Deutzmann A; Yarbrough J; Krishnan MS; Gouw AM; Bellovin DI; Adam SJ; Liefwalker DF; Dhanasekaran R; Felsher DW
Oncogene; 2022 Nov; 41(45):4960-4970. PubMed ID: 36207533
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis.
Yue M; Jiang J; Gao P; Liu H; Qing G
Cell Rep; 2017 Dec; 21(13):3819-3832. PubMed ID: 29281830
[TBL] [Abstract][Full Text] [Related]
26. MYC activation is a hallmark of cancer initiation and maintenance.
Gabay M; Li Y; Felsher DW
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
[TBL] [Abstract][Full Text] [Related]
27. Developmental context determines latency of MYC-induced tumorigenesis.
Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW
PLoS Biol; 2004 Nov; 2(11):e332. PubMed ID: 15455033
[TBL] [Abstract][Full Text] [Related]
28. Triterpene Acid (
Choi HS; Kim SL; Kim JH; Deng HY; Yun BS; Lee DS
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149665
[TBL] [Abstract][Full Text] [Related]
29. The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.
Lancho O; Herranz D
Trends Cancer; 2018 Dec; 4(12):810-822. PubMed ID: 30470303
[TBL] [Abstract][Full Text] [Related]
30. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
Cho MH; Park JH; Choi HJ; Park MK; Won HY; Park YJ; Lee CH; Oh SH; Song YS; Kim HS; Oh YH; Lee JY; Kong G
Nat Commun; 2015 Jul; 6():7821. PubMed ID: 26199140
[TBL] [Abstract][Full Text] [Related]
31. DNA Damage Signaling-Induced Cancer Cell Reprogramming as a Driver of Tumor Relapse.
Filipponi D; Emelyanov A; Muller J; Molina C; Nichols J; Bulavin DV
Mol Cell; 2019 May; 74(4):651-663.e8. PubMed ID: 30954402
[TBL] [Abstract][Full Text] [Related]
32. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.
Nair R; Roden DL; Teo WS; McFarland A; Junankar S; Ye S; Nguyen A; Yang J; Nikolic I; Hui M; Morey A; Shah J; Pfefferle AD; Usary J; Selinger C; Baker LA; Armstrong N; Cowley MJ; Naylor MJ; Ormandy CJ; Lakhani SR; Herschkowitz JI; Perou CM; Kaplan W; O'Toole SA; Swarbrick A
Oncogene; 2014 Jul; 33(30):3992-4002. PubMed ID: 24056965
[TBL] [Abstract][Full Text] [Related]
33. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.
Ahmadiyeh N; Pomerantz MM; Grisanzio C; Herman P; Jia L; Almendro V; He HH; Brown M; Liu XS; Davis M; Caswell JL; Beckwith CA; Hills A; Macconaill L; Coetzee GA; Regan MM; Freedman ML
Proc Natl Acad Sci U S A; 2010 May; 107(21):9742-6. PubMed ID: 20453196
[TBL] [Abstract][Full Text] [Related]
34. Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis.
Carroll PA; Diolaiti D; McFerrin L; Gu H; Djukovic D; Du J; Cheng PF; Anderson S; Ulrich M; Hurley JB; Raftery D; Ayer DE; Eisenman RN
Cancer Cell; 2015 Feb; 27(2):271-85. PubMed ID: 25640402
[TBL] [Abstract][Full Text] [Related]
35. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
36. Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer.
Chu PY; Hou MF; Lai JC; Chen LF; Lin CS
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013830
[TBL] [Abstract][Full Text] [Related]
37. A Versatile In Vivo System to Study Myc in Cell Reprogramming.
Senís E; Mosteiro L; Grimm D; Abad M
Methods Mol Biol; 2021; 2318():267-279. PubMed ID: 34019296
[TBL] [Abstract][Full Text] [Related]
38. The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis.
Xiao JF; Sun QY; Ding LW; Chien W; Liu XY; Mayakonda A; Jiang YY; Loh XY; Ran XB; Doan NB; Castor B; Chia D; Said JW; Tan KT; Yang H; Fu XY; Lin DC; Koeffler HP
J Pathol; 2018 Sep; 246(1):89-102. PubMed ID: 29926931
[TBL] [Abstract][Full Text] [Related]
39. Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.
Hirsch CL; Coban Akdemir Z; Wang L; Jayakumaran G; Trcka D; Weiss A; Hernandez JJ; Pan Q; Han H; Xu X; Xia Z; Salinger AP; Wilson M; Vizeacoumar F; Datti A; Li W; Cooney AJ; Barton MC; Blencowe BJ; Wrana JL; Dent SY
Genes Dev; 2015 Apr; 29(8):803-16. PubMed ID: 25877919
[TBL] [Abstract][Full Text] [Related]
40. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
